호흡기세포융합바이러스 진단 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Respiratory Syncytial Virus Diagnostics Market Size, Share & Trends Analysis Report By Product (DFA, RADT, Molecular Diagnostics, Chromatographic Immunoassay), By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,836,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,322,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,292,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

호흡기세포융합바이러스 진단 시장 성장과 동향

그랜드 뷰 리서치(Grand View Research, Inc.)의 최신 보고서에 따르면, 세계 호흡기세포융합바이러스 진단 시장 규모는 2025-2030년 동안 연평균 5.81%의 CAGR로 성장하여 2030년에는 87억 달러에 달할 것으로 예상됩니다. 신생아 인구의 증가와 의료 제공자의 신생아 진단을 위한 지원 이니셔티브는 RSV 진단 시장의 중요한 영향력 촉진요인이 될 것으로 예상됩니다.

WHO 통계에 따르면, 미국에서는 2014년에 15만 명 이상의 어린이(5세 이하)가 RSV 감염으로 입원했고, 약 14,000명의 노인 환자가 사망했습니다. 이는 예측 기간 동안 이러한 질병에 대한 검사 수요를 유발할 것으로 예상됩니다.

또한 2014년 현재 세계 출산율은 1,000명당 18.7명으로 향후 7년간 영유아 인구가 크게 증가할 것으로 예상됩니다. 통계에 따르면 2014년에는 약 1억 3,420만 명의 출산이 있었던 것으로 추정되며, 이러한 출산은 RSV 감염에 걸리기 쉽고 진단이 필요하기 때문에 큰 시장 기반을 형성하고 있습니다.

2010년 Save Babies Through Screening Foundation(SBTS)은 World Solutions Against Infectious Disease(WSAID)와 파트너십을 맺고 신생아 감염성 질환, 대사 장애, 청각 장애에 대한 신생아 감염, 대사장애, 청각장애에 대한 검진을 추진하기 위한 시도를 시작했습니다.

호흡기세포융합바이러스 진단 시장 보고서 하이라이트

• 크로마토그래피 면역측정법은 분자진단보다 특이도가 높아 향후 7년간 2024년 시장 점유율 27.38%로 시장을 장악했습니다. 시판 중인 검사 키트에는 Binax Now RSV, QuickLab RSV Test, Remel Xpect, RSV Respi-Strip 등이 있습니다.
• 병원 부문은 2024년 41.09%의 점유율로 시장을 장악하고 예측 기간 동안 가장 빠른 성장률을 보일 것으로 예상됩니다. 환자들의 홈케어 진단 장비에 대한 수요 증가는 향후 7년간 이 부문의 성장을 견인할 것으로 예측됩니다.
• 북미는 2024년까지 41.18% 이상의 매출 점유율을 차지하며 시장을 장악했습니다. 신생아 검진을 시작 및 실시하기 위한 주민들의 인식 증가와 WHO, PAHO, WSAID와 같은 정부 기관의 호의적인 노력은 성장을 촉진할 것으로 예상됩니다.
• 이 시장의 주요 기업인 NovartisAG, Abbott, BD and Company, Ortho Clinical Diagnostics, Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific Inc. Roche Diagnostics, Becton Dickinson and Company, Alere Inc. 등의 CLIA 승인 및 RSV 분석의 출시는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 호흡기세포융합바이러스 진단 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 호흡기세포융합바이러스 진단 시장 분석 툴
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 호흡기세포융합바이러스 진단 시장 : 제품별, 추정·동향 분석

• 세계의 호흡기세포융합바이러스 진단 시장 : 제품 대시보드
• 세계의 호흡기세포융합바이러스 진단 시장 : 제품 변동 분석
• 세계의 호흡기세포융합바이러스 진단 시장(제품별, 매출별)
• 직접 형광 항체법(DFA)
• 신속 항원 진단 검사(RADT)
• 분자진단
• 크로마토그래피 면역측정법
  • 중력 구동 테스트
  • 올리고 크로마토그래피(OC)
• 진단 영상
• 겔 마이크로 드롭렛
• 유세포 분석
• 기타

제5장 호흡기세포융합바이러스 진단 시장 : 최종 용도별, 추정·동향 분석

• 세계의 호흡기세포융합바이러스 진단 시장 : 최종 용도 대시보드
• 세계의 호흡기세포융합바이러스 진단 시장 : 최종 용도 변동 분석
• 세계의 호흡기세포융합바이러스 진단 시장(최종 용도, 매출별)
• 병원
• 실험실
• 클리닉
• 기타

제6장 호흡기세포융합바이러스 진단 시장 : 제품, 최종 용도에 의한 지역별, 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 진출 기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 상황
  • 주요 판매대리점과 채널 파트너 리스트
  • 주요 기업의 시장 점유율 분석, 2024년
  • BD(Becton, Dickinson, and Company)
  • Novartis AG
  • Abbott
  • QuidelOrtho Corporation
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • BIOMERIEUX
  • DiaSorin SpA
  • Merck KGaA
  • Coris BioConcept
  • Siemens Healthineers AG
  • Quest Diagnostics Incorporated

ksm

영문 목차

영문목차

Respiratory Syncytial Virus Diagnostics Market Growth & Trends:

The global respiratory syncytial virus diagnostics market size is estimated to reach USD 8.70 billion by 2030, expanding at a CAGR of 5.81% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing neonatal population suffering from respiratory conditions including RSV infections and supportive initiatives for diagnosis of newborns by the healthcare providers are expected to be vital impact rendering drivers for RSV diagnostics market.

According to the statistics provided by the WHO, hospitalization of over 150,000 children (below the age of five) and about 14,000 deaths in geriatric patients occurred in the U.S. in 2014 due to RSV infections. This is anticipated to trigger demand for testing of these conditions over the forecast period.

Furthermore, the global birth rate as of 2014 is 18.7 births per 1,000 individuals, which is predicted to increase the infant population substantially over the next seven years. According to the statistics, it is estimated that about 134.2 million births took place in 2014, which are prone to RSV infections and require diagnosis, thus forming a large market base.

In 2010, Save Babies Through Screening Foundation (SBTS) entered in a partnership with World Solutions Against Infectious Disease (WSAID) as an attempt to promote higher screening of newborns for infectious diseases, metabolic disorders, and hearing disabilities.

Respiratory Syncytial Virus Diagnostics Market Report Highlights:

• Chromatographic immunoassay segment dominated the market with a share of 27.38% in 2024 over the next seven years owing to their higher specificity than molecular diagnostic products. The commercially available test kits include Binax Now RSV, QuickLab RSV Test, Remel Xpect, and RSV Respi-Strip.
• Hospitals segment dominated the market with a share of 41.09% in 2024 and is anticipated to grow at fastest growth rate over the forecast period. Increasing demand for home care diagnostic devices by patients is anticipated to drive growth of the segment over the next seven years.
• North America is anticipated to dominate the market and contribute a revenue share of over 41.18% by 2024. Rising awareness among the population base and favorable initiatives by the government agencies such as the WHO, PAHO, and WSAID to initiate and implement newborn screening are expected to drive growth.
• Key players of the market include Novartis AG, Abbott, BD and Company, Ortho Clinical Diagnostics, Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific Inc. CLIA waiver and launch of RSV assays by companies like Roche Diagnostics, Becton Dickinson and Company, and Alere Inc. are expected to boost market growth over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. End use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and End use outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Respiratory Syncytial Virus Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of Respiratory Syncytial Virus (RSV) Infections
    • 3.2.1.2. Advancements in diagnostics technologies
    • 3.2.1.3. Growing awareness and healthcare spending
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost associated with advanced diagnostic tests
    • 3.2.2.2. Lack of awareness in developing reagions
• 3.3. Respiratory Syncytial Virus Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Social landscape
    • 3.3.2.5. Environmental landscape

Chapter 4. Respiratory Syncytial Virus Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Global Respiratory Syncytial Virus Diagnostics Market: Product Dashboard
• 4.2. Global Respiratory Syncytial Virus Diagnostics Market: Product Movement Analysis
• 4.3. Global Respiratory Syncytial Virus Diagnostics Market by Product , Revenue
• 4.4. Direct Fluorescent Antibody (DFA) Method
• 4.5. Rapid Antigen Diagnostic Test (RADTs)
  • 4.5.1. Rapid Antigen Diagnostic Test (RADTs) market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.6. Molecular Diagnostics
  • 4.6.1. Molecular diagnostics market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.7. Chromatographic Immunoassay
  • 4.7.1. Chromatography immunoassay market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.7.2. Gravity Driven Test
    • 4.7.2.1. Gravity driven test market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.7.3. Oligochromatography (OC)
    • 4.7.3.1. Oligochromatography (OC) market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.8. Diagnostic Imaging
  • 4.8.1. Diagnostic imaging market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.9. Gel Microdroplets
  • 4.9.1. Gel microdroplets market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.10. Flow Cytometry
  • 4.10.1. Flow cytometry market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.11. Others
  • 4.11.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Respiratory Syncytial Virus Diagnostics Market: End use Estimates & Trend Analysis

• 5.1. Global Respiratory Syncytial Virus Diagnostics Market: End use Dashboard
• 5.2. Global Respiratory Syncytial Virus Diagnostics Market: End use Movement Analysis
• 5.3. Global Respiratory Syncytial Virus Diagnostics Market by End use, Revenue
• 5.4. Hospitals
  • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.5. Laboratory
  • 5.5.1. Laboratory market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.6. Clinics
  • 5.6.1. Clinics market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Respiratory Syncytial Virus Diagnostics Market: Regional Estimates & Trend Analysis by Type, Tube Material, Application, and End use

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
  • 7.3.4. BD (Becton, Dickinson, and Company)
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Novartis AG
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Abbott
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. QuidelOrtho Corporation
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Thermo Fisher Scientific Inc.
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Bio-Rad Laboratories, Inc.
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. F. Hoffmann-La Roche Ltd.
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. BIOMERIEUX
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. DiaSorin S.p.A.
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Merck KGaA
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. Coris BioConcept
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives
  • 7.3.15. Siemens Healthineers AG
    • 7.3.15.1. Company overview
    • 7.3.15.2. Financial performance
    • 7.3.15.3. Product benchmarking
    • 7.3.15.4. Strategic initiatives
  • 7.3.16. Quest Diagnostics Incorporated
    • 7.3.16.1. Company overview
    • 7.3.16.2. Financial performance
    • 7.3.16.3. Product benchmarking
    • 7.3.16.4. Strategic initiatives

관련자료